Skip Navigation Links

Bookmark and Share
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
Collaboration is based on Oncodesign’s Nanocyclix® technology and TiumBio’s fibrosis-centered R&D expertise  Agreement also foresees option for in-licensing global development and commercialization rights for TiumBio DIJON, France & PANGYO, S...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.